Overview
Amino tadalafil is described as a tadalafil-related analog with molecular mass 390.4 g/mol and formula C21H18N4O4. Its interest comes from the well-characterized pharmacology of tadalafil, a phosphodiesterase type 5 inhibitor, but amino tadalafil itself does not have the same approved-drug evidence base. For peptide users, the key distinction is simple: similarity to a known drug does not establish potency, purity, duration, or safety.
PDE5 inhibitors work by preserving cyclic GMP signaling in smooth muscle. When nitric oxide activates guanylate cyclase, cGMP rises and supports smooth-muscle relaxation; PDE5 normally breaks cGMP down. A tadalafil-like analog may therefore be studied for vasodilation pathways, but small structural changes can alter receptor selectivity, metabolism, off-target activity, and interaction risk.
This entry is not FDA-approved for any therapeutic use. Prescription tadalafil products have labeling, dose ranges, contraindications, and adverse-event surveillance; amino tadalafil research material does not. It should be treated as an investigational chemical, especially because unapproved PDE5 analogs have appeared in adulterated supplements and may be misidentified or present at unknown strengths.
This guide covers the expected PDE5-related mechanism, the limits of extrapolating from tadalafil, practical safety concerns, and why nitrates, alpha-blockers, cardiovascular disease, and CYP3A4 inhibitors are central risk areas for this class.
Quick facts
- Mechanism
- Investigational tadalafil analog expected to modulate PDE5-cGMP signaling
- Primary use
- PDE5 Inhibition Research
- Evidence
- limited
- FDA
- Not approved
- Route
- Research use only; no approved human route
- Typical results
- PDE5-style signaling expected from structural similarity, with analog-specific human data lacking
Chemical information
Amino tadalafil is a small-molecule tadalafil analog rather than a peptide, with formula C21H18N4O4 and molecular mass 390.4 g/mol. Its heterocyclic scaffold is structurally related to tadalafil, but analog identity does not establish pharmaceutical equivalence.
How Amino Tadalafil works
Amino tadalafil is discussed through the pharmacology of the tadalafil scaffold. PDE5 inhibition reduces enzymatic breakdown of cGMP in responsive smooth muscle, allowing nitric-oxide signaling to produce relaxation of vascular and cavernosal tissue. The practical problem is that analog status does not define actual potency or selectivity. Without published human PK and safety data, assumptions should be conservative.
In the approved-drug model, tadalafil binds PDE5 and prolongs cGMP action. That can support vasodilation in tissues where nitric oxide signaling is active. Tadalafil's long duration comes from its own absorption, protein binding, metabolism, and elimination profile. Amino tadalafil may not share those parameters. Even if the core target is similar, analog-specific substitutions can change onset, tissue distribution, and unwanted PDE activity.
Risk management for this class is driven by hemodynamics and metabolism. Combining a PDE5 inhibitor with nitrates can produce dangerous hypotension because both increase the nitric oxide-cGMP pathway. Strong CYP3A4 inhibitors can raise exposure for tadalafil-like compounds if the analog uses similar metabolic routes. Because amino tadalafil lacks an approved label, users should not infer safe dose timing, stacking practices, or washout periods.
- PDE5 inhibition: Expected to reduce cGMP breakdown in smooth muscle
- NO pathway dependence: Effects require upstream nitric-oxide signaling
- Vasodilation: May relax vascular or cavernosal smooth muscle in research models
- Analog uncertainty: Small structural changes can shift potency and selectivity
- CYP risk: Tadalafil-related compounds may be affected by CYP3A4 inhibitors
- Nitrate contraindication: Additive cGMP signaling can cause dangerous blood pressure drops
Pharmacokinetics
Published human pharmacokinetics for amino tadalafil could not be confidently identified. Tadalafil PK can inform class-level caution, but half-life, metabolism, and exposure for this analog should be treated as unknown.
| Parameter | Value | Significance |
|---|---|---|
| Human PK | Not established | No reliable amino tadalafil half-life or exposure data found |
| Reference scaffold | Tadalafil | Approved tadalafil has known PDE5 pharmacology, but the analog may differ |
| Metabolism | Unknown; CYP3A4 concern by analogy | Strong inhibitors may increase exposure if routes overlap |
| Duration | Unknown | Do not assume tadalafil's long duration applies |
| Bioavailability | Unknown | Research material has no approved oral or injectable profile |
| Onset | Unknown | No dependable timing guidance exists |
Dosing & administration
No FDA-approved dosing exists for amino tadalafil. Research discussion sometimes borrows from tadalafil, but that is not scientifically safe because analog potency, purity, and metabolism may differ. Any number presented as a human protocol would be speculative unless tied to a validated clinical study.
Approved tadalafil has specific labeled doses, warnings, and washout guidance. Amino tadalafil does not. The conservative position is to treat it as a laboratory compound for receptor or analytical work, not as a human-use medication, especially in anyone using cardiovascular drugs.
Because unapproved PDE5 analogs have been found in sexual-enhancement products, identity testing matters. HPLC purity, mass confirmation, and contaminant screening are more important than anecdotal reports of effect.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
Amino tadalafil carries the class risks of PDE5 inhibition plus the additional uncertainty of an unapproved analog. Cardiovascular disease, nitrates, alpha-blockers, antihypertensives, and unknown product identity are the main practical safety concerns.
Common
- • Headache
- • Flushing
- • Nasal congestion
- • Dyspepsia or reflux
- • Back or muscle aches by class analogy
- • Lightheadedness from vasodilation
Serious / potential risks
- • Severe hypotension, especially with nitrates
- • Priapism by PDE5-inhibitor class risk
- • Sudden vision or hearing symptoms reported with PDE5 inhibitors
- • Cardiovascular events in vulnerable users
- • Unknown toxicology from unapproved analog exposure
Drug interactions
Interaction guidance is extrapolated from tadalafil and PDE5-inhibitor labeling because amino tadalafil lacks its own approved interaction studies.
| Medication | Interaction | Recommendation |
|---|---|---|
| Nitrates | Additive cGMP signaling can cause severe hypotension | Avoid; this is a major class contraindication |
| Riociguat | Combined cGMP pathway effects may dangerously lower blood pressure | Avoid by PDE5-inhibitor class labeling |
| Alpha-blockers | May increase orthostatic hypotension | Medical supervision required for approved PDE5 inhibitors; avoid analog self-use |
| Strong CYP3A4 inhibitors | May raise tadalafil-like exposure if metabolism overlaps | Avoid extrapolated stacking without clinical data |
| Antihypertensives or alcohol | May add to dizziness and blood pressure lowering | Use class-level caution |
Storage & handling
Lyophilized (powder)
- • Store at -20°C to 4°C (freezer or refrigerator)
- • Protect from light and moisture
- • Stable for 12–24 months when stored properly
- • Keep in original sealed container until reconstitution
Reconstituted solution
- • Refrigerate at 2–8°C after reconstitution
- • Use bacteriostatic water for multi-dose reconstitution
- • Typical stability: 14–28 days refrigerated
- • Do not freeze reconstituted solution
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Research chemical suppliers | $50-$200+ per gram or vial equivalent | Pricing varies; identity confirmation is essential |
| Analytical testing | $100-$400+ per sample | LC-MS is useful for analog confirmation |
| Approved tadalafil comparison | Generic prescription pricing varies widely | Approved drug has labeling and quality controls that research analogs lack |
The bottom line
Amino tadalafil should be viewed as an investigational PDE5-inhibitor analog, not a tadalafil replacement. The biology of PDE5 inhibition is well understood, but analog-specific dosing, PK, safety, and purity are not. The nitrate and cardiovascular cautions that apply to PDE5 inhibitors are especially important.
Best for
- • Analytical reference work on PDE5-inhibitor analogs
- • In vitro PDE5 signaling research
- • Researchers comparing tadalafil-like chemical scaffolds
Not for
- • Self-treatment of erectile dysfunction or performance goals
- • Use with nitrates, riociguat, or unstable cardiovascular disease
- • Assuming tadalafil dosing applies to an unapproved analog
- • Products without identity and purity testing
Related compounds
Acetic Acid
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
AOD-9604
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Astressin-B
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
B7-33
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Frequently asked questions
References
- [1] Forgue ST, Patterson BE, Bedding AW, et al.. Tadalafil pharmacokinetics in healthy subjects. British Journal of Clinical Pharmacology (2006). PMID: 16869816
- [2] U.S. Food and Drug Administration. CIALIS (tadalafil) prescribing information. FDA Label (2024).
- [3] Huang SA, Lie JD. Phosphodiesterase-5 inhibitors in the management of erectile dysfunction. P&T (2013). PMID: 24223089
- [4] Venhuis BJ, de Kaste D. Scientific opinion on adulterants in sexual enhancement supplements. RIVM Report (2012).
- [5] National Center for Biotechnology Information. Tadalafil. StatPearls (2025).
- [6] National Center for Biotechnology Information. PubChem Compound Summary for Tadalafil. PubChem (2026).